Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials
Abstract Objective Raised plasma endothelin-1 (ET-1) levels may be a risk factor for vascular dysfunction and cardiovascular (CV) disease. This meta-analysis assessed the effect of statins on circulating ET-1 concentrations. Methods and results The search included PUBMED, Cochrane Library, Web of Sc...
Gespeichert in:
| Veröffentlicht in: | Atherosclerosis 2015-08, Vol.241 (2), p.433-442 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 442 |
|---|---|
| container_issue | 2 |
| container_start_page | 433 |
| container_title | Atherosclerosis |
| container_volume | 241 |
| creator | Sahebkar, Amirhossein Kotani, Kazuhiko Serban, Corina Ursoniu, Sorin Mikhailidis, Dimitri P Jones, Steven R Ray, Kausik K Blaha, Michael J Rysz, Jacek Toth, Peter P Muntner, Paul Lip, Gregory Y.H Banach, Maciej |
| description | Abstract Objective Raised plasma endothelin-1 (ET-1) levels may be a risk factor for vascular dysfunction and cardiovascular (CV) disease. This meta-analysis assessed the effect of statins on circulating ET-1 concentrations. Methods and results The search included PUBMED, Cochrane Library, Web of Science, Scopus, and EMBASE up to September 30, 2014 to identify randomized controlled trials (RCTs) with ET-1 measurement during statin therapy. Quantitative data synthesis was performed using a random-effects model, with weighed mean difference (WMD) and 95% confidence interval (CI) as summary statistics. Data from 15 RCTs showed that statin therapy significantly reduces plasma ET-1 concentrations (WMD: −0.30 pg/mL, 95%CI: −0.47, −0.13; p |
| doi_str_mv | 10.1016/j.atherosclerosis.2015.05.022 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1698030631</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0021915015013362</els_id><sourcerecordid>1698030631</sourcerecordid><originalsourceid>FETCH-LOGICAL-c565t-f7c98a609248934c375da1eb06a24a9164b924fec8939f1eebea272cfaebc4c23</originalsourceid><addsrcrecordid>eNqNUU2LFDEQDaK44-pfkFwELz3mq9PdgsKy6CoseFg9h-p0NWZMd8YkLYy_3oRZPexJKFIF9V5V6j1CXnG254zrN4c95O8YQ7K-vi7tBePtnpUQ4hHZ8b4bGq569ZjsGBO8GXjLLsizlA6MMdXx_im5EJp1SvJuR5a7DNmttM6E44lGnDaLiR49pAUorlMoLe_WhlMbVotrjoUQ1vSWXtEFMzSwgj-Vj9AwU97SCIWzuN84VUKOwftS5ujAp-fkyVwSvrjPl-Tbxw9frz81t19uPl9f3Ta21W1u5s4OPWg2CNUPUlnZtRNwHJkGoWDgWo2lNaMt3WHmiCOC6ISdAUerrJCX5PV57jGGnxumbBaXLHoPK4YtGa6HnkmmJS_Qd2eoLWqmiLM5RrdAPBnOTFXcHMwDxU1V3LASoq56eb9qGxec_rH_SlwAN2cAloN_OYwmWYdFyclFtNlMwf33qvcPJtlijLPgf-AJ0yFssVhRrjNJGGbuqv3V_RpSaiH_APe2ss0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1698030631</pqid></control><display><type>article</type><title>Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Sahebkar, Amirhossein ; Kotani, Kazuhiko ; Serban, Corina ; Ursoniu, Sorin ; Mikhailidis, Dimitri P ; Jones, Steven R ; Ray, Kausik K ; Blaha, Michael J ; Rysz, Jacek ; Toth, Peter P ; Muntner, Paul ; Lip, Gregory Y.H ; Banach, Maciej</creator><creatorcontrib>Sahebkar, Amirhossein ; Kotani, Kazuhiko ; Serban, Corina ; Ursoniu, Sorin ; Mikhailidis, Dimitri P ; Jones, Steven R ; Ray, Kausik K ; Blaha, Michael J ; Rysz, Jacek ; Toth, Peter P ; Muntner, Paul ; Lip, Gregory Y.H ; Banach, Maciej ; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group</creatorcontrib><description><![CDATA[Abstract Objective Raised plasma endothelin-1 (ET-1) levels may be a risk factor for vascular dysfunction and cardiovascular (CV) disease. This meta-analysis assessed the effect of statins on circulating ET-1 concentrations. Methods and results The search included PUBMED, Cochrane Library, Web of Science, Scopus, and EMBASE up to September 30, 2014 to identify randomized controlled trials (RCTs) with ET-1 measurement during statin therapy. Quantitative data synthesis was performed using a random-effects model, with weighed mean difference (WMD) and 95% confidence interval (CI) as summary statistics. Data from 15 RCTs showed that statin therapy significantly reduces plasma ET-1 concentrations (WMD: −0.30 pg/mL, 95%CI: −0.47, −0.13; p < 0.01). This effect was robust in sensitivity analysis, and not largely affected by the duration of statin therapy (<12 weeks – WMD: −0.51 pg/mL, 95%CI: −0.89, −0.14, p < 0.01; >12 week –WMD: −0.19 pg/mL, 95%CI: −0.36, −0.02; p < 0.05) or by dose of statins (<40 mg/day – WMD: −0.27 pg/mL, 95%CI: −0.49, −0.05; p = 0.01; >40 mg/day – WMD: −0.38 pg/mL, 95%CI: −0.68, −0.08; p = 0.01). Lipophilic (atorvastatin, simvastatin, fluvastatin, and cerivastatin – WMD: −0.34 pg/mL, 95%CI: −0.55, −0.13; p < 0.01), but not a hydrophilic statin (pravastatin – WMD: −0.18 pg/mL, 95%CI: −0.44 −0.08; p > 0.05) had a significant effect in promoting ET-1 reduction. Conclusions Statin therapy significantly reduces circulating ET-1 concentrations, regardless of treatment duration or dose of statins. This effect of statins may be influenced by statin lipophilicity. There is a need to establish whether lowering ET-1 levels has a beneficial effect on CV events.]]></description><identifier>ISSN: 0021-9150</identifier><identifier>EISSN: 1879-1484</identifier><identifier>DOI: 10.1016/j.atherosclerosis.2015.05.022</identifier><identifier>PMID: 26074317</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Adult ; Aged ; Biomarkers - blood ; Cardiovascular ; Chi-Square Distribution ; Dyslipidemias - blood ; Dyslipidemias - diagnosis ; Dyslipidemias - drug therapy ; Endothelial dysfunction ; Endothelin-1 ; Endothelin-1 - blood ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Lipids - blood ; Lipophilicity ; Male ; Middle Aged ; Odds Ratio ; Randomized Controlled Trials as Topic ; Statins ; Therapy ; Treatment Outcome</subject><ispartof>Atherosclerosis, 2015-08, Vol.241 (2), p.433-442</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2015 Elsevier Ireland Ltd</rights><rights>Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c565t-f7c98a609248934c375da1eb06a24a9164b924fec8939f1eebea272cfaebc4c23</citedby><cites>FETCH-LOGICAL-c565t-f7c98a609248934c375da1eb06a24a9164b924fec8939f1eebea272cfaebc4c23</cites><orcidid>0000-0001-6690-6874</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.atherosclerosis.2015.05.022$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26074317$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sahebkar, Amirhossein</creatorcontrib><creatorcontrib>Kotani, Kazuhiko</creatorcontrib><creatorcontrib>Serban, Corina</creatorcontrib><creatorcontrib>Ursoniu, Sorin</creatorcontrib><creatorcontrib>Mikhailidis, Dimitri P</creatorcontrib><creatorcontrib>Jones, Steven R</creatorcontrib><creatorcontrib>Ray, Kausik K</creatorcontrib><creatorcontrib>Blaha, Michael J</creatorcontrib><creatorcontrib>Rysz, Jacek</creatorcontrib><creatorcontrib>Toth, Peter P</creatorcontrib><creatorcontrib>Muntner, Paul</creatorcontrib><creatorcontrib>Lip, Gregory Y.H</creatorcontrib><creatorcontrib>Banach, Maciej</creatorcontrib><creatorcontrib>Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group</creatorcontrib><title>Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials</title><title>Atherosclerosis</title><addtitle>Atherosclerosis</addtitle><description><![CDATA[Abstract Objective Raised plasma endothelin-1 (ET-1) levels may be a risk factor for vascular dysfunction and cardiovascular (CV) disease. This meta-analysis assessed the effect of statins on circulating ET-1 concentrations. Methods and results The search included PUBMED, Cochrane Library, Web of Science, Scopus, and EMBASE up to September 30, 2014 to identify randomized controlled trials (RCTs) with ET-1 measurement during statin therapy. Quantitative data synthesis was performed using a random-effects model, with weighed mean difference (WMD) and 95% confidence interval (CI) as summary statistics. Data from 15 RCTs showed that statin therapy significantly reduces plasma ET-1 concentrations (WMD: −0.30 pg/mL, 95%CI: −0.47, −0.13; p < 0.01). This effect was robust in sensitivity analysis, and not largely affected by the duration of statin therapy (<12 weeks – WMD: −0.51 pg/mL, 95%CI: −0.89, −0.14, p < 0.01; >12 week –WMD: −0.19 pg/mL, 95%CI: −0.36, −0.02; p < 0.05) or by dose of statins (<40 mg/day – WMD: −0.27 pg/mL, 95%CI: −0.49, −0.05; p = 0.01; >40 mg/day – WMD: −0.38 pg/mL, 95%CI: −0.68, −0.08; p = 0.01). Lipophilic (atorvastatin, simvastatin, fluvastatin, and cerivastatin – WMD: −0.34 pg/mL, 95%CI: −0.55, −0.13; p < 0.01), but not a hydrophilic statin (pravastatin – WMD: −0.18 pg/mL, 95%CI: −0.44 −0.08; p > 0.05) had a significant effect in promoting ET-1 reduction. Conclusions Statin therapy significantly reduces circulating ET-1 concentrations, regardless of treatment duration or dose of statins. This effect of statins may be influenced by statin lipophilicity. There is a need to establish whether lowering ET-1 levels has a beneficial effect on CV events.]]></description><subject>Adult</subject><subject>Aged</subject><subject>Biomarkers - blood</subject><subject>Cardiovascular</subject><subject>Chi-Square Distribution</subject><subject>Dyslipidemias - blood</subject><subject>Dyslipidemias - diagnosis</subject><subject>Dyslipidemias - drug therapy</subject><subject>Endothelial dysfunction</subject><subject>Endothelin-1</subject><subject>Endothelin-1 - blood</subject><subject>Female</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Lipids - blood</subject><subject>Lipophilicity</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Odds Ratio</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Statins</subject><subject>Therapy</subject><subject>Treatment Outcome</subject><issn>0021-9150</issn><issn>1879-1484</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUU2LFDEQDaK44-pfkFwELz3mq9PdgsKy6CoseFg9h-p0NWZMd8YkLYy_3oRZPexJKFIF9V5V6j1CXnG254zrN4c95O8YQ7K-vi7tBePtnpUQ4hHZ8b4bGq569ZjsGBO8GXjLLsizlA6MMdXx_im5EJp1SvJuR5a7DNmttM6E44lGnDaLiR49pAUorlMoLe_WhlMbVotrjoUQ1vSWXtEFMzSwgj-Vj9AwU97SCIWzuN84VUKOwftS5ujAp-fkyVwSvrjPl-Tbxw9frz81t19uPl9f3Ta21W1u5s4OPWg2CNUPUlnZtRNwHJkGoWDgWo2lNaMt3WHmiCOC6ISdAUerrJCX5PV57jGGnxumbBaXLHoPK4YtGa6HnkmmJS_Qd2eoLWqmiLM5RrdAPBnOTFXcHMwDxU1V3LASoq56eb9qGxec_rH_SlwAN2cAloN_OYwmWYdFyclFtNlMwf33qvcPJtlijLPgf-AJ0yFssVhRrjNJGGbuqv3V_RpSaiH_APe2ss0</recordid><startdate>20150801</startdate><enddate>20150801</enddate><creator>Sahebkar, Amirhossein</creator><creator>Kotani, Kazuhiko</creator><creator>Serban, Corina</creator><creator>Ursoniu, Sorin</creator><creator>Mikhailidis, Dimitri P</creator><creator>Jones, Steven R</creator><creator>Ray, Kausik K</creator><creator>Blaha, Michael J</creator><creator>Rysz, Jacek</creator><creator>Toth, Peter P</creator><creator>Muntner, Paul</creator><creator>Lip, Gregory Y.H</creator><creator>Banach, Maciej</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6690-6874</orcidid></search><sort><creationdate>20150801</creationdate><title>Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials</title><author>Sahebkar, Amirhossein ; Kotani, Kazuhiko ; Serban, Corina ; Ursoniu, Sorin ; Mikhailidis, Dimitri P ; Jones, Steven R ; Ray, Kausik K ; Blaha, Michael J ; Rysz, Jacek ; Toth, Peter P ; Muntner, Paul ; Lip, Gregory Y.H ; Banach, Maciej</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c565t-f7c98a609248934c375da1eb06a24a9164b924fec8939f1eebea272cfaebc4c23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biomarkers - blood</topic><topic>Cardiovascular</topic><topic>Chi-Square Distribution</topic><topic>Dyslipidemias - blood</topic><topic>Dyslipidemias - diagnosis</topic><topic>Dyslipidemias - drug therapy</topic><topic>Endothelial dysfunction</topic><topic>Endothelin-1</topic><topic>Endothelin-1 - blood</topic><topic>Female</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Lipids - blood</topic><topic>Lipophilicity</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Odds Ratio</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Statins</topic><topic>Therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sahebkar, Amirhossein</creatorcontrib><creatorcontrib>Kotani, Kazuhiko</creatorcontrib><creatorcontrib>Serban, Corina</creatorcontrib><creatorcontrib>Ursoniu, Sorin</creatorcontrib><creatorcontrib>Mikhailidis, Dimitri P</creatorcontrib><creatorcontrib>Jones, Steven R</creatorcontrib><creatorcontrib>Ray, Kausik K</creatorcontrib><creatorcontrib>Blaha, Michael J</creatorcontrib><creatorcontrib>Rysz, Jacek</creatorcontrib><creatorcontrib>Toth, Peter P</creatorcontrib><creatorcontrib>Muntner, Paul</creatorcontrib><creatorcontrib>Lip, Gregory Y.H</creatorcontrib><creatorcontrib>Banach, Maciej</creatorcontrib><creatorcontrib>Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Atherosclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sahebkar, Amirhossein</au><au>Kotani, Kazuhiko</au><au>Serban, Corina</au><au>Ursoniu, Sorin</au><au>Mikhailidis, Dimitri P</au><au>Jones, Steven R</au><au>Ray, Kausik K</au><au>Blaha, Michael J</au><au>Rysz, Jacek</au><au>Toth, Peter P</au><au>Muntner, Paul</au><au>Lip, Gregory Y.H</au><au>Banach, Maciej</au><aucorp>Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials</atitle><jtitle>Atherosclerosis</jtitle><addtitle>Atherosclerosis</addtitle><date>2015-08-01</date><risdate>2015</risdate><volume>241</volume><issue>2</issue><spage>433</spage><epage>442</epage><pages>433-442</pages><issn>0021-9150</issn><eissn>1879-1484</eissn><abstract><![CDATA[Abstract Objective Raised plasma endothelin-1 (ET-1) levels may be a risk factor for vascular dysfunction and cardiovascular (CV) disease. This meta-analysis assessed the effect of statins on circulating ET-1 concentrations. Methods and results The search included PUBMED, Cochrane Library, Web of Science, Scopus, and EMBASE up to September 30, 2014 to identify randomized controlled trials (RCTs) with ET-1 measurement during statin therapy. Quantitative data synthesis was performed using a random-effects model, with weighed mean difference (WMD) and 95% confidence interval (CI) as summary statistics. Data from 15 RCTs showed that statin therapy significantly reduces plasma ET-1 concentrations (WMD: −0.30 pg/mL, 95%CI: −0.47, −0.13; p < 0.01). This effect was robust in sensitivity analysis, and not largely affected by the duration of statin therapy (<12 weeks – WMD: −0.51 pg/mL, 95%CI: −0.89, −0.14, p < 0.01; >12 week –WMD: −0.19 pg/mL, 95%CI: −0.36, −0.02; p < 0.05) or by dose of statins (<40 mg/day – WMD: −0.27 pg/mL, 95%CI: −0.49, −0.05; p = 0.01; >40 mg/day – WMD: −0.38 pg/mL, 95%CI: −0.68, −0.08; p = 0.01). Lipophilic (atorvastatin, simvastatin, fluvastatin, and cerivastatin – WMD: −0.34 pg/mL, 95%CI: −0.55, −0.13; p < 0.01), but not a hydrophilic statin (pravastatin – WMD: −0.18 pg/mL, 95%CI: −0.44 −0.08; p > 0.05) had a significant effect in promoting ET-1 reduction. Conclusions Statin therapy significantly reduces circulating ET-1 concentrations, regardless of treatment duration or dose of statins. This effect of statins may be influenced by statin lipophilicity. There is a need to establish whether lowering ET-1 levels has a beneficial effect on CV events.]]></abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>26074317</pmid><doi>10.1016/j.atherosclerosis.2015.05.022</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-6690-6874</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-9150 |
| ispartof | Atherosclerosis, 2015-08, Vol.241 (2), p.433-442 |
| issn | 0021-9150 1879-1484 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1698030631 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adult Aged Biomarkers - blood Cardiovascular Chi-Square Distribution Dyslipidemias - blood Dyslipidemias - diagnosis Dyslipidemias - drug therapy Endothelial dysfunction Endothelin-1 Endothelin-1 - blood Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Lipids - blood Lipophilicity Male Middle Aged Odds Ratio Randomized Controlled Trials as Topic Statins Therapy Treatment Outcome |
| title | Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T15%3A20%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Statin%20therapy%20reduces%20plasma%20endothelin-1%20concentrations:%20A%20meta-analysis%20of%2015%20randomized%20controlled%20trials&rft.jtitle=Atherosclerosis&rft.au=Sahebkar,%20Amirhossein&rft.aucorp=Lipid%20and%20Blood%20Pressure%20Meta-analysis%20Collaboration%20(LBPMC)%20Group&rft.date=2015-08-01&rft.volume=241&rft.issue=2&rft.spage=433&rft.epage=442&rft.pages=433-442&rft.issn=0021-9150&rft.eissn=1879-1484&rft_id=info:doi/10.1016/j.atherosclerosis.2015.05.022&rft_dat=%3Cproquest_cross%3E1698030631%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1698030631&rft_id=info:pmid/26074317&rft_els_id=S0021915015013362&rfr_iscdi=true |